Nick McAndrew, MD MSCE Updates in Breast CancerSummary of 2019 practice changing studies @MOASC_Office @dgsomucla

Nick McAndrew, MD MSCE Updates in Breast CancerSummary of 2019 practice changing studies @MOASC_Office @dgsomucla

User Photo
moasc

6 months
25 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in Breast CancerSummary of 2019 practice changing studies Overall Survival UpdatesCDK 4/6 Inhibitors: MONALEESA 3, 7 and MONARCH 2, Adjuvant Pertuzumab: APHINITY, ER+, First PI3K Inhibitor Approval: SOLAR-1, HER2+, Tyrosine Kinase Inhibitors: NALA, HER2CLIMB, New ADC: DESTINY-Breast01Triple Negative, Checkpoint Inhibitor in mBC: IMpassion130 Neoadjuvant Checkpoint Inhibitors: KEYNOTE-522, NeoTRIP at the MOASC Summit 2020

Sponsors:

AbbVie 

AMAG

AstraZeneca 

Bayer 

BeiGene 

Clovis Oncology

Coherus 

Daiichi-Sankyo 

Dova Pharmaceuticals 

Foundation Medicine 

Jazz Pharmaceuticals  

Merck 

Pfizer Oncology 

Puma Biotechnology 

Tempus 

Verastem oncology

Walgreens 

Up Next Autoplay